Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

New therapeutic approaches for spondyloarthritis.

Manadan AM, James N, Block JA.

Curr Opin Rheumatol. 2007 May;19(3):259-64. Review.

PMID:
17414952
2.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

PMID:
12819466
3.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

4.

Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.

De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Verbruggen G, Mielants H, Veys E.

Drugs. 2004;64(24):2793-811. Review.

PMID:
15563249
5.

Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.

Kavanaugh A, Tutuncu Z, Catalan-Sanchez T.

Curr Opin Rheumatol. 2006 Jul;18(4):347-53. Review.

PMID:
16763453
6.

[Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].

Langer HE.

Wien Med Wochenschr. 2008;158(7-8):200-5. doi: 10.1007/s10354-008-0522-2. Review. German.

PMID:
18500471
7.

Ankylosing spondylitis: new treatment modalities.

Brandt J, Marzo-Ortega H, Emery P.

Best Pract Res Clin Rheumatol. 2006 Jun;20(3):559-70. Review.

PMID:
16777582
8.

Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.

Henderson C, Davis JC.

Nat Clin Pract Rheumatol. 2006 Apr;2(4):211-8. Review.

PMID:
16932687
9.

Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?

Haibel H, Sieper J.

Curr Opin Rheumatol. 2010 Jul;22(4):388-92. doi: 10.1097/BOR.0b013e32833aaf93. Review.

PMID:
20473176
10.

Novel therapies for ankylosing spondylitis.

Maksymowych WP.

Curr Rheumatol Rep. 2005 Jun;7(3):182-7. Review.

PMID:
15918993
11.

Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.

Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.

Ann Rheum Dis. 2010 Jun;69(6):1065-71. doi: 10.1136/ard.2009.111187. Epub 2009 Sep 9.

PMID:
19740906
12.

Anti-TNF-alpha therapy in ankylosing spondylitis.

De Keyser F, Van den Bosch F, Mielants H.

Cytokine. 2006 Mar 7;33(5):294-8. Epub 2006 Mar 3. Review.

PMID:
16516484
13.

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.

Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J.

Ann Rheum Dis. 2008 Sep;67(9):1276-81. Epub 2007 Nov 15.

PMID:
18006539
14.

TNF antagonists for ankylosing spondylitis.

[No authors listed]

Drug Ther Bull. 2005 Mar;43(3):19-22. Review.

PMID:
15762384
15.

Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, Marzo-Ortega H, Mielants H.

Ann Rheum Dis. 2002 Dec;61 Suppl 3:iii51-60. Review.

16.

Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.

Song IH, Maksymowych WP.

Rheum Dis Clin North Am. 2012 Aug;38(3):613-33. doi: 10.1016/j.rdc.2012.08.004. Epub 2012 Sep 15. Review.

PMID:
23083759
17.

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Gorman JD, Sack KE, Davis JC Jr.

N Engl J Med. 2002 May 2;346(18):1349-56.

PMID:
11986408
18.

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2005 Dec 15;53(6):856-63.

19.

[Anti-TNF alfa therapy in ankylosing spondylitis].

Cravo AR, Tavares V, Da Silva JC.

Acta Med Port. 2006 Mar-Apr;19(2):141-50. Epub 2006 Aug 18. Review. Portuguese.

20.

The anti-TNF revolution in ankylosing spondylitis: patients with severe disease now have access to promising new drugs.

Schachna L.

Med J Aust. 2004 Nov 15;181(10):529-30. No abstract available.

PMID:
15540959

Supplemental Content

Support Center